Veltio Pharma Joins UIC Accelerate to Propel Novel Innovations

Veltio Pharma has taken an important step forward by joining the UIC Accelerate program at Uppsala Innovation Centre. This two-year accelerator will provide the company with tailored business coaching and strategic support to grow its nanotechnology-based oral formulation platform. This move aims to help Veltio Pharma bring more effective and sustainable therapies to the market.

What UIC Accelerate Means for Veltio Pharma

Being accepted into UIC Accelerate gives Veltio Pharma access to a network of experts and resources designed to support startups and scale-ups in the life sciences sector. The program focuses on helping companies refine their business models, improve product development, and prepare for market expansion.

This support will be crucial as Veltio Pharma works to advance its oral drug formulations, which use nanotechnology to improve drug delivery and patient outcomes.

The Promise of Nanotechnology in Oral Formulations

Nanotechnology offers exciting possibilities in medicine, especially for oral drug delivery. By manipulating materials at the nanoscale, Veltio Pharma can enhance the solubility and absorption of drugs that traditionally face challenges in these areas. This can lead to therapies that are not only more effective but also require lower doses, reducing side effects and improving patient compliance.

Veltio Pharma’s platform focuses on:

• Improving the bioavailability of poorly soluble drugs.

• Creating formulations that are easier to manufacture and scale.

• Offering sustainable alternatives by reducing the need for complex excipients.

  
  

These innovations have the potential to impact a wide range of therapeutic areas, making treatments more accessible and affordable.

CEO Stina Lundgren’s Vision

Stina Lundgren, CEO of Veltio Pharma, highlights the significance of joining UIC Accelerate: “The UIC Accelerate programme provides exactly the framework and network we need to take the next step. It’s an exciting milestone for Veltio Pharma.”

Her statement reflects the company’s confidence in the program’s ability to help them overcome growth challenges and accelerate their path to market. The support from UIC Accelerate will allow Veltio Pharma to focus on refining their technology and expanding their reach.